Anavex Life Sciences Corp
Closed
SectorHealthcare
2.41
Overview
Share price change
24h
Min
2.31
Max
2.43
Income | 14M 7.8M |
|---|---|
EPS | 0.08 |
Employees | 34 |
EBITDA | 3.3M -3.2M |
Next Earnings | 24 Nov 2026 |
|---|
Market Cap | -47M 241M |
|---|---|
Previous open | 2.41 |
Previous close | 2.41 |
News Sentiment
By Acuity
41%
59%
103 / 339 Healthcare
Anavex Life Sciences Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Anavex Life Sciences Corp Forecast
Sentiment
By Acuity
103 / 339 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Interest expense on debt
EBITDA
Operating profit
$
About Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.